Review of Liver Fibrosis and Inflammation

Open Access

Issue		BIO Web Conf. Volume 232, 2026 2026 16^th International Conference on Bioscience, Biochemistry and Bioinformatics (ICBBB 2026)


Article Number		04008
Number of page(s)		22
Section		Natural Products Pharmacology and Therapeutic Mechanisms
DOI		https://doi.org/10.1051/bioconf/202623204008
Published online		24 April 2026

H. Devarbhavi, SK. Asrani, JP. Arab, YA. Narte, et al. Global burden of liver disease: 2023 update. Journal of hepatology, 79(2), 516–537(2023). https://doi.org/10.1016/jjhep.2023.03.017) [Google Scholar]
D. Razavi-Shearer, I. Gamkrelidze, C. Pan, et al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. The lancet. Gastroenterology & hepatology, 8(10), 879–907 (2023). https://doi.org/10.1016/S2468-1253(23)00197-8 [Google Scholar]
C. Gan, Y. Yuan, H. Shen,. et al. Liver diseases: epidemiology, causes, trends and predictions. Sig Transduct Target Ther. 10, 33 (2025). https://doi.org/10.1038/s41392-024-02072-z [Google Scholar]
Z. M. Younossi, P. Golabi, J. M. Paik, The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, Md. ), 77(4), 1335–1347 (2023). https://doi.org/10.1097/HEP.0000000000000004 [Google Scholar]
R. Loomba, S. L. Friedman, G. I. Shulman. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 184(10), 2537–2564 (2021). https://doi.org/10.1016/j.cell.2021.04.015 [Google Scholar]
P. Kasper, A. Martin, S. Lang, NAFLD and cardiovascular diseases: a clinical review. Clinical research in cardiology : official journal of the German Cardiac Society, 110(7), 921–937 (2021). https://doi.org/10.1007/s00392-020-01709-7 [Google Scholar]
F. Åberg, Z. G Jiang, H. Cortez-Pinto, et al. Alcohol-associated liver disease-Global epidemiology. Hepatology (Baltimore, Md. ), 80(6), 1307–1322 (2024). https://doi.org/10.1097/HEP.0000000000000899 [Google Scholar]
W. Liang, X. Huang, J. Shi. Macrophages Serve as Bidirectional Regulators and Potential Therapeutic Targets for Liver Fibrosis. Cell Biochem Biophys 81, 659–671 (2023). https://doi.org/10.1007/s12013-023-01173-wUSED2 [Google Scholar]
F. D. Wang, J. Zhou, E. Q. Chen. Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis. Frontiers in pharmacology, 13, 787748 (2022). https://doi.org/10.3389/fphar.2022.787748 [Google Scholar]
D. Ye, R. Jingyi, Y. Hongqiang. Roles of pathogen-associated and damage-associated molecular patterns in immune inflammatory response[J]. Inter J Stomatol, 2016, 43(2): 172–176. [Google Scholar]
N. Nasiri-Ansari, T. Androutsakos, C. M. Flessa, et al. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells, 11(16), 2511 (2022)https://doi.org/10.3390/cells11162511 [Google Scholar]
L. Ceci, E. Gaudio, L. Kennedy. Cellular Interactions and Crosstalk Facilitating Biliary Fibrosis in Cholestasis. Cellular and molecular gastroenterology and hepatology, 17(4), 553–565 (2024). https://doi.org/10.1016/jjcmgh.2024.01.005 [Google Scholar]
C. Ding, Z. Wang, X. Dou, et al. Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis. Aging and disease, 15(4), 1508–1536(2024). https://doi.org/10.14336/AD.2023.0830 [Google Scholar]
JL. Lu, CX. Yu, LJ. Song. Programmed cell death in hepatic fibrosis: current and perspectives. Cell Death Discov. 9, 449 (2023). https://doi.org/10.1038/s41420-023-01749-8 [Google Scholar]
M. Robinson, C. Harmon, C. O'Farrelly. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol 13, 267–276 (2016). https://doi.org/10.1038/cmi.2016.3 [Google Scholar]
C. Ju, F. Tacke. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol 13, 316–327 (2016). https://doi.org/10.1038/cmi.2015.104 [Google Scholar]
D. R. Kamm, K. S. McCommis. Hepatic stellate cells in physiology and pathology. The Journal of physiology, 600(8), 1825–1837(2022)https://doi.org/10.1113/JP281061 [Google Scholar]
A. E. Barry, R. Baldeosingh, R. Lamm, et al. Hepatic Stellate Cells and Hepatocarcinogenesis. Frontiers in cell and developmental biology, 8, 709 (2020). https://doi.org/10.3389/fcell.2020.00709 [Google Scholar]
A. Sharip, J. Kunz. Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy. Cells, 14(4), 266(2025). https://doi.org/10.3390/cells14040266 [Google Scholar]
M. Puri, S. Sonawane. Liver Sinusoidal Endothelial Cells in the Regulation of Immune Responses and Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. International journal of molecular sciences, 26(9), 3988(2025). https://doi.org/10.3390/ijms26093988 [Google Scholar]
B. Gao, A. Waisman. Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone. Gastroenterology, 143(3), 536–539(2012) https://doi.org/10.1053/j.gastro.2012.07.031 [Google Scholar]
Y. J. Yang, F. Huang. Role of hepatic stellate cells and correlated cytokines in the formation of hepatic fibrosis. Shijie Huaren Xiaohua Zazhi 2007; 15(27): 2885–2890 [DOI: 10.11569/wcjd.v15.i27.2885]. [Google Scholar]
CS. Pavlov, G. Casazza, D. Nikolova, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD010542. DOI: 10.1002/14651858.CD010542.pub2 [Google Scholar]
R. Bataller, D. A. Brenner. Liver fibrosis. The Journal of clinical investigation, 115(2), 209–218 (2005). https://doi.org/10.1172/JCI24282 [Google Scholar]
T. Kisseleva, D. Brenner. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18, 151–166 (2021). https://doi.org/10.1038/s41575-020-00372-7 [Google Scholar]
M. Sun, T. Kisseleva. Reversibility of liver fibrosis. Clinics and research in hepatology and gastroenterology, 39 Suppl 1(01), S60-S63 (2015). https://doi.org/10.1016/j.clinre.2015.06.015 [Google Scholar]
X. Ma, J. Qiu, S. Zou, et al. The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies. Frontiers in immunology, 15, 1494250(2024). https://doi.org/10.3389/fimmu.2024.1494250 [Google Scholar]
Y. H. Li, Y. Zhang, G. Pan, et al. Occurrences and Functions of Ly6Chi and Ly6Clo Macrophages in Health and Disease. Frontiers in immunology, 13, 901672(2022). https://doi.org/10.3389/fimmu.2022.901672 [Google Scholar]
E. Seki, R. F. Schwabe. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology (Baltimore, Md. ), 61(3), 1066–1079 (2015). https://doi.org/10.1002/hep.27332 [Google Scholar]
A. Moreno-Lanceta, M. Medrano-Bosch, Y. Fundora,. RNF41 orchestrates macrophage-driven fibrosis resolution and hepatic regeneration. Science translational medicine, 15(704), eabq6225(2023).. https://doi.org/10.1126/scitranslmed.abq6225 [Google Scholar]
J. S. Troeger, I. Mederacke, G. Y. Gwak, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology, 143(4), 1073–83. e22 (2012). https://doi.org/10.1053/j.gastro.2012.06.036 [Google Scholar]
X. Dong, J. Liu, Y. Xu, et al. Role of macrophages in experimental liver injury and repair in mice. Experimental and therapeutic medicine, 17(5), 3835–3847(2019). https://doi.org/10.3892/etm.2019.7450 [Google Scholar]
S. K. Wculek, G. Dunphy, I. Heras-Murillo, Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol 19, 384–408 (2022). https://doi.org/10.1038/s41423-021-00791-9 [Google Scholar]
Y. Wen, J. Lambrecht, C. Ju, et al. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 18, 45–56 (2021). https://doi.org/10.1038/s41423-020-00558-8 [Google Scholar]
N. Wang, H. Liang, K. Zen. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Frontiers in immunology, 5, 614 (2014). https://doi.org/10.3389/fimmu.2014.00614 [Google Scholar]
J. Xu, G. Núñez. The NLRP3 inflammasome: activation and regulation. Trends in biochemical sciences, 48(4), 331–344(2023). https://doi.org/10.1016/j.tibs.2022.10.002 [Google Scholar]
T. Tsuchida, S. L. Friedman. Mechanisms of hepatic stellate cell activation. Nature reviews. Gastroenterology & hepatology, 14(7), 397–411 (2017). https://doi.org/10.1038/nrgastro.2017.38 [Google Scholar]
X. Du, Z. Wu, Y. Xu, et al. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice. Cellular & molecular immunology, 16(11), 878–886(2019). https://doi.org/10.1038/s41423-018-0032-0 [Google Scholar]
T. Shan, L. Qian, C. Yang, et. al. (2021). Effect of interaction between hepatic macrophages and hepatic stellate cells on the occurrence and reversion of hepatic fibrosis. Chinese Bulletin of Life Sciences, 33(3), 363–373(2021). [Google Scholar]
E. Seki, S. de Minicis, S. Inokuchi, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology (Baltimore, Md. ), 50(1), 185–197. (2009). https://doi.org/10.1002/hep.22952 [Google Scholar]
F. Marra, F. Tacke. Roles for chemokines in liver disease. Gastroenterology, 147(3), 577–594,(2014). e1. https://doi.org/10.1053/j.gastro.2014.06.043 [Google Scholar]
E. Seki, S. De Minicis, G. Y. Gwak, et. al. CCR1 and CCR5 promote hepatic fibrosis in mice. The Journal of clinical investigation, 119(7), 1858–1870(2009). https://doi.org/10.1172/jci37444 [Google Scholar]
R. Sasaki, P. B. Devhare, R. Steele, et. al. Hepatitis C virus-induced CCL5 secretion from macrophages activates hepatic stellate cells. Hepatology (Baltimore, Md. ), 66(3), 746–757(2017).. https://doi.org/10.1002/hep.29170 [Google Scholar]
Y. S. Roh, E. Seki. Chemokines and Chemokine Receptors in the Development of NAFLD. Advances in experimental medicine and biology, 1061, 45–53(2018). https://doi.org/10.1007/978-981-10-8684-74 [Google Scholar]
A. Ambade, P. Lowe, K. Kodys, et al. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice. Hepatology (Baltimore, Md. ), 69(3), 1105–1121(2019). https://doi.org/10.1002/hep.30249 [Google Scholar]
E. Lefebvre, Moyle, G. Reshef, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PloS one, 11(6), e0158156 (2016). https://doi.org/10.1371/journal.pone.0158156 [Google Scholar]
C. Wang, C. Ma, L. Gong, et al. Macrophage Polarization and Its Role in Liver Disease. Frontiers in immunology, 12, 803037(2021). https://doi.org/10.3389/fimmu.2021.803037 [Google Scholar]
R. Chen, H. Zhang, B. Tang, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Sig Transduct Target Ther 9, 130 (2024). https://doi.org/10.1038/s41392-024-01840-1 [Google Scholar]
J. Chen, S. Zhang. The Role of Inflammation in Cholestatic Liver Injury. Journal of inflammation research, 16, 4527–4540(2023). https://doi.org/10.2147/JIR.S430730 [Google Scholar]
Y. A. Ni, H. Chen, H. Nie, et al. HMGB1 : An overview of its roles in the pathogenesis of liver disease. Journal of leukocyte biology, 110(5), 987–998 (2021). https://doi.org/10.1002/JLB.3MR0121-277R [Google Scholar]
W. Ying, M. Riopel, G. Bandyopadhyay, et al. Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity. Cell, 171(2), 372–384. e12(2017). https://doi.org/10.1016/j.cell.2017.08.035 [Google Scholar]
J. Wan, M. Benkdane, F. Teixeira-Clerc, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology (Baltimore, Md. ), 59(1), 130–142 (2014).. https://doi.org/10.1002/hep.26607 [Google Scholar]
L. J. Kitto, N. C. Henderson. Hepatic Stellate Cell Regulation of Liver Regeneration and Repair. Hepatology communications, 5(3), 358–370(2020). https://doi.org/10.1002/hep4.1628 [Google Scholar]
A. Zisser, D. H. Ipsen, P. Tveden-Nyborg. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets? Biomedicines, 9(4), 365(2021). https://doi.org/10.3390/biomedicines9040365 [Google Scholar]
Y. Q. Zhao, X. W. Deng, G. Q. Xu, et al. Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis. Frontiers in molecular biosciences, 10, 1183808 (2023). https://doi.org/10.3389/fmolb.2023.1183808 [Google Scholar]
L. Hammerich, F. Tacke, Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol 20, 633–646 (2023). https://doi.org/10.1038/s41575-023-00807-x [Google Scholar]
C. Y. Zhang, W. G. Yuan, P. He,et al. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World journal of gastroenterology, 22(48), 10512–10522(2016). https://doi.org/10.3748/wjg.v22.i48.10512 [Google Scholar]
T. Tsuchida, S. Friedman. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14, 397–411 (2017). https://doi.org/10.1038/nrgastro.2017.38 [Google Scholar]
H. Z. Ying, Q. Chen, W. Y. Zhang, et al. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). Molecular medicine reports, 16(6), 7879–7889(2017). https://doi.org/10.3892/mmr.2017.7641 [Google Scholar]
F. Rangwala, C. D. Guy, J. Lu, et al. Increased production of sonic hedgehog by ballooned hepatocytes. The Journal of pathology, 224(3), 401–410(2011). https://doi.org/10.1002/path.2888 [Google Scholar]
D. Povero, N. Panera, A. Eguchi, et al. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-y. Cellular and molecular gastroenterology and hepatology, 1(6), 646–663. e4 (2015). https://doi.org/10.1016/j.jcmgh.2015.07.007 [Google Scholar]
A. Herchenhan, F. Uhlenbrock, P. Eliasson, et al. Lysyl Oxidase Activity Is Required for Ordered Collagen Fibrillogenesis by Tendon Cells. The Journal of biological chemistry, 290(26), 16440–16450(2015). https://doi.org/10.1074/jbc.M115.641670 [Google Scholar]
L. Wiering, P. Subramanian, L. & Hammerich. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease. Cellular and molecular gastroenterology and hepatology, 15(6), 1277–1292 (2023). https://doi.org/10.1016/j.jcmgh.2023.02.010 [Google Scholar]
N. Frangogiannis. Transforming growth factor-ß in tissue fibrosis. The Journal of experimental medicine, 217(3), e20190103(2020). https://doi.org/10.1084/jem.20190103 [Google Scholar]
J. Gong, J. Han, J. He, et al. Paired related homeobox protein 1 regulates PDGF-induced chemotaxis of hepatic stellate cells in liver fibrosis. Lab Invest 97, 1020–1032 (2017). https://doi.org/10.1038/labinvest.2017.65 [Google Scholar]
Maeso-Díaz, R., & Gracia-Sancho, J. (2020). Aging and chronic liver disease. Seminars in Liver Disease, 40(4), 373–384. https://doi.org/10.1055/s-0040-1715446 [Google Scholar]
S. P. Tang, X. L. Mao, Y. H. Chen, et al. Reactive Oxygen Species Induce Fatty Liver and Ischemia-Reperfusion Injury by Promoting Inflammation and Cell Death. Frontiers in immunology, 13, 870239(2022).. https://doi.org/10.3389/fimmu.2022.870239 [Google Scholar]
N. Kelley, D. Jeltema, Y. Duan,et al. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. International journal of molecular sciences, 20(13), 3328(2019). https://doi.org/10.3390/ijms20133328 [Google Scholar]
S. Guo, Q. Zhang, Y. Guo, X. Yin. et al. The role and therapeutic targeting of the CCL2/CCR2 signaling axis in inflammatory and fibrotic diseases. Frontiers in immunology, 15, 1497026 (2025). https://doi.org/10.3389/fimmu.2024.1497026 [Google Scholar]
S. Bouffette, I. Botez, F. De Ceuninck. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends in pharmacological sciences, 44(8), 519–531 (2023). https://doi.org/10.1016/j.tips.2023.06.001 [Google Scholar]
J. F. Calver, N. R. Parmar, G. Harris, et al. Defining the mechanism of galectin-3-mediated TGF-ß1 activation and its role in lung fibrosis. The Journal of biological chemistry, 300(6), 107300(2024). https://doi.org/10.1016/j.jbc.2024.107300 [Google Scholar]
L. Zhao, H. Tang, Z. Cheng. Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances. Pharmaceuticals, 17(12), 1724 (2024)https://doi.org/10.3390/ph17121724 [Google Scholar]
R. Nevola, R. Epifani, S. Imbriani, G. Tortorella,et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International journal of molecular sciences, 24(2), 1703 (2023). https://doi.org/10.3390/ijms24021703 [Google Scholar]
V. Ratziu, A. Sanyal, S. A. Harrison, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology, 72(3), 892–905(2020). [Google Scholar]
R. B. Holmgaard, D. A. Schaer, Y. Li, et al. Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for immunotherapy of cancer, 6(1), 47(2018). https://doi.org/10.1186/s40425-018-0356-4 [Google Scholar]
Y. Aono, Y. Nishioka, M. Inayama, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. American journal of respiratory and critical care medicine, 171(11), 1279–1285(2005). https://doi.org/10.1164/rccm.200404-531OC [Google Scholar]
S. Dhani, Y. Zhao, B. Zhivotovsky. A long way to go: caspase inhibitors in clinical use. Cell death & disease, 12(10), 949 (2021). https://doi.org/10.1038/s41419-021-04240-3 [Google Scholar]
S. Hwang, Y. He, X. Xiang, et al. Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets. Hepatology (Baltimore, Md. ), 72(2), 412–429(2020). https://doi.org/10.1002/hep.31031 [Google Scholar]
H. Dai, C. Zhu, Q. Huai,et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. Journal of hepatology, 80(6), 913–927 (2024)https://doi.org/10.1016/j.jhep.2024.01.034 [Google Scholar]
S. Hiltbrunner, C. Britschgi, P. Schuberth, et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Annals of Oncology, 32(1), 120–121 (2021).. https://doi.org/10.5167/uzh-193552 [Google Scholar]
A. Albillos, A. de Gottardi, M. Rescigno. The gut-liver axis in liver disease: Pathophysiological basis for therapy. Journal of hepatology, 72(3), 558–577(2020). https://doi.org/10.1016/j.jhep.2019.10.003 [Google Scholar]
Y. Yan, Q. Lv, F. Zhou, et al. Discovery of an effective anti-inflammatory agent for inhibiting the activation of NF-kB. Journal of enzyme inhibition and medicinal chemistry, 38(1), 2225135 (2023). https://doi.org/10.1080/14756366.2023.2225135 [Google Scholar]
F. Perner, H. L. Pahl, R. Zeiser, et al. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia 39, 1011–1030 (2025). https://doi.org/10.1038/s41375-025-02569-8 [Google Scholar]
W. Ouyang, A. O'Garra. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity, 50(4), 871–891 (2019). https://doi.org/10.1016/j.immuni.2019.03.020 [Google Scholar]
X. Song, C. Jiang, M. Yu, et al. CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis. Journal of gastroenterology and hepatology, 39(8), 1597–1605(2024). https://doi.org/10.1111/jgh.16622 [Google Scholar]
A. Gonzalez-Rodriguez, A. M. Valverde. RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases. Current pharmaceutical design, 21(31), 4574–4586(2015). https://doi.org/10.2174/138161282131151013190740 [Google Scholar]
Z. Q. Yao, M. B. Schank, J. Zhao, et al. The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption. Frontiers in genome editing, 6, 1467449(2024)https://doi.org/10.3389/fgeed.2024.1467449 [Google Scholar]
P. Dalsbecker, C. Beck Adiels, M. Goksör. Liver-on-a-chip devices: the pros and cons of complexity. American journal ofphysiology. Gastrointestinal and liver physiology, 323(3), G188-G204(2022). https://doi.org/10.1152/ajpgi.00346.2021 [Google Scholar]
K. Somnay, P. Wadgaonkar, N. Sridhar, et al. Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives. Biomedicines, 12(10), 2229(2024). https://doi.org/10.3390/biomedicines12102229 [Google Scholar]
S. Hafeez, M. H. Ahmed. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?. Journal of obesity, 2013, 839275(2013). https://doi.org/10.1155/2013/839275 [Google Scholar]
Y. Liu, C. Meyer, C. Xu, et al. Animal models of chronic liver diseases. American journal of physiology. Gastrointestinal and liver physiology, 304(5), G449-G468(2013)https://doi.org/10.1152/ajpgi.00199.2012 [Google Scholar]
J. Li, B. Tuo. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterology research and practice, 2021, 6612892, (2021). https://doi.org/10.1155/2021/6612892 [Google Scholar]
X. Li, Y. Liu, Y. Tang, et al. Transformation of macrophages into myofibroblasts in fibrosis-related diseases: emerging biological concepts and potential mechanism. Frontiers in immunology, 15, 1474688(2024). https://doi.org/10.3389/fimmu.2024.1474688 [Google Scholar]
S. Shetty, P. F. Lalor, D. H. Adams, Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol 15, 555–567 (2018). https://doi.org/10.1038/s41575-018-0020-y [Google Scholar]
Z. J. Brown, B. Heinrich, T. F. Greten. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nature reviews. Gastroenterology & hepatology, 15(9), 536–554, (2018). https://doi.org/10.1038/s41575-018-0033-6 [Google Scholar]
L. J. Kitto, N. C. Henderson. Hepatic Stellate Cell Regulation of Liver Regeneration and Repair. Hepatology communications, 5(3), 358–370 (2020). https://doi.org/10.1002/hep4.1628 [Google Scholar]
X. Dong, J. Liu, Y. Xu, et al. Role of macrophages in experimental liver injury and repair in mice. Experimental and therapeutic medicine, 17(5), 3835–3847(2019). https://doi.org/10.3892/etm.2019.7450 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.